PRRT2 and ovarian carcinoma: In the epithelial ovarian cancer, an increased expression of Wnt5a and PKCα was significantly correlated with metastasis of the disease, and the PKCα inhibitor could reduce the metastatic capacity [18]; in OSCC, Wnt5a was found to promote the migration and invasion of cancer cells through activation of noncanonical Wnt/Calcium/PKC pathway [20].